Is Inhibrx Biosciences Inc. (INBX) a Buy, Sell, or Hold?
NASDAQ : INBX
Inhibrx Biosciences Inc.
$81.55 USD
-$3.45 (-4.06%)
- Volume
- 164.94K
- Average Volume
- 401.63K
- Market Capitalization
- $1.2B
- P/E Ratio
- -9.72
- Dividend Yield
- 0.00%
- Price Target
- $325.00
- Year High
- $155.29
- Year Low
- $20.55
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.46
Company Overview
NASDAQ
Mark Lappe
Biotechnology
Healthcare
INBX
109
US
USD
Liquidity Metrics
-0.28
6.46
6.46
6.10
0.00
Sales & Valuation
$1.3M
920.33
-60.42
-9.07
-8.47
Profitability
-$9.04
-$140.06M
-10014.23%
-10014.08%
-563.89%
-70.77%
P/E Metrics
-9.72
0.09
0.09
Analyst Price Target & Rating
$325.00
$325.00
$325.00
2/5
5 Analysts
-74.91%
Financial Health Scores
0.20
3/9
$144.83M
$183.97M
$205M
-$118.44M
Key Metrics (TTM)
$1.04B
800.52
-8.96
6.46
-563.89%
-76.97%
-10.24%
-11.03%
-1312 days
Company Executives
| Name | Title |
|---|---|
| David Matly | President |
| Josep Garcia | Executive Vice President & Chief Clinical Development Officer |
| Mark Paul Lappe | Founder, Chief Executive Officer & Chairman |
| Carlos Bais | EVice President & Chief Scientific Officer |
| Ashraf Amanullah | Executive Vice President & Chief Technical Operations Officer |
| Bonne Adams | Vice President of Operations |
| Leah Pollema | Vice President, General Counsel & Corporate Secretary |
| Kate Burke | Vice President of Accounting |
| Kelly Devine Deck | Executive Vice President, Chief Financial Officer & Treasurer |
Poll Results
No votes yet today — be the first to share your view!
About Inhibrx Biosciences Inc. (NASDAQ:INBX) Stock
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA. ...
Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act
2026-07-17 06:43:05
Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers. Ozekibart's BLA for chondrosarcoma is under FDA review with an April 14, 2027 PDUFA date, supported by strong PFS and disease control data. INBRX-106 shows promising early efficacy as a PD-1 enhancer in HNSCC, with pivotal PFS data expected in Q4 2026 and Phase 3 initiation in Q3 2026.
2026-07-16 09:00:00
SAN DIEGO, July 16, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced it entered into the Second Amendment (the "Second Amendment") to the Loan and Security Agreement, as amended (the "Amended LSA") with Oxford Finance LLC ("Oxford," together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders expanded the facility to an aggregate principal amount of up to $500.0 million (the "Credit Facility"). The Second Amendment provides for an additional tranche, in an aggregate principal amount of up to $325.0 million in gross proceeds, (i) $100.0 million of which was funded upon execution of the Second Amendment (the "Term C Loan") and (ii) up to an additional $225.0 million of which may be funded in increments of $50.0 million or more upon the Company's request and at the Lenders' sole discretion (the "Term D Loan").
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice
2026-07-09 13:01:16
Does Inhibrx Biosciences, Inc. (INBX) have what it takes to be a top stock pick for momentum investors? Let's find out.
2026-06-15 09:15:00
No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027 If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma SAN DIEGO, June 15, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its Biologics License Application (BLA) seeking approval of ozekibart (INBRX-109) for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. The FDA has not identified any filing review issues at this time and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027.
Inhibrx Reports First Quarter 2026 Financial Results
2026-05-14 16:02:00
SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials.
Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study
2026-05-11 13:57:59
Inhibrx Biosciences, Inc. (NASDAQ:INBX) shares are trading higher on Monday as the company is reporting positive interim results from its Phase 2 study of INBRX-106 in combination with Merck & Co. Inc.'s (NYSE:MRK) Keytruda (pembrolizumab) for treating head and neck cancer.
Inhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study
2026-05-11 12:09:25
Inhibrx Biosciences NASDAQ: INBX reported interim randomized Phase 2 data for INBRX-106 in combination with Merck's KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with Chief Executive Officer Mark Lappe saying the results showed a higher confirmed response rate and deeper tumor reductions versus KEYTRUDA alone.
2026-05-11 08:00:00
Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population, the INBRX-106 + pembrolizumab combination achieved a cORR of 44.0% versus 21.4% with pembrolizumab alone, representing a 22.6% absolute increase in cORR. Superior depth of response: Responding patients in the combination arm demonstrated deeper tumor reductions overall, with the majority achieving target lesion shrinkage exceeding 50%; notably, three patients achieved a complete radiographic response.
Frequently Asked Questions
-
What is the current Inhibrx Biosciences Inc. (INBX) stock price?
-
Inhibrx Biosciences Inc.(NASDAQ:INBX) stock price is $81.55 in the last trading session. During the trading session, INBX stock reached the peak price of $155.29 while $20.55 was the lowest point it dropped to. The percentage change in INBX stock occurred in the recent session was --4.06% while the dollar amount for the price change in INBX stock was -$3.45.
-
INBX's industry and sector of operation?
-
The NASDAQ listed INBX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of INBX?
-
David Matly | President
Josep Garcia | Executive Vice President & Chief Clinical Development Officer
Mark Paul Lappe | Founder, Chief Executive Officer & Chairman
Carlos Bais | EVice President & Chief Scientific Officer
Ashraf Amanullah | Executive Vice President & Chief Technical Operations Officer -
How many employees does INBX have?
-
Number of INBX employees currently stands at 109. INBX operates from 11025 North Torrey Pines Road, La Jolla, CA 92037, US.
-
Link for INBX official website?
-
Official Website of INBX is: https://www.inhibrx.com
-
How do I contact INBX?
-
INBX could be contacted at phone #858-795-4220 and can also be accessed through its website. INBX operates from 11025 North Torrey Pines Road, La Jolla, CA 92037, US.
-
How many shares of INBX are traded daily?
-
The average number of INBX shares traded daily for last 3 months was 401.63K.
-
What is the market cap of INBX currently?
-
The market value of INBX currently stands at $1.2B with its latest stock price at $81.55